The TRAIL Receptor-Ligand System: Biochemistry of Apoptosis Induction, Therapeutic Potential for Cancer Treatment and Physiological Function

Apoptosis and Cancer Therapy: From Cutting-edge Science to Novel Therapeutic Concepts

Volumn 1, Issue , 2008, Pages 31-92

  Walczak, Henning ^a   Koschny, Ronald ^a   Willen, Daniela ^a   Schader, Manuela B ^a   Sykora, Jaromir ^a   Ganten, Tom M ^b   Haas, Tobias L ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biochemistry; Genetic aberrations; Physiological function; Signaling; Tumor tissue

Indexed keywords

EID: 78349278718     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619665.ch2     Document Type: Chapter

References (312)

1. Kelley, S. K. and A. Ashkenazi. 2004. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 4:333-339.
2. Wiley, S. R., K. Schooley, P. J. Smolak, W S. Din, C. P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch, C. A. Smith and R. G. Goodwin. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682.
3. Wang, S. and W. S. El-Deiry. 2003. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22:8628-8633.
4. Kim, Y. and D. W. Seol. 2003. TRAIL, a mighty apoptosis inducer. Mol Cell 15:283-293.
5. LeBlanc, H. N. and A. Ashkenazi. 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10:66-75.
6. Pan, G., K. O'Rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni and V M. Dixit. 1997. The receptor for the cytotoxic ligand TRAIL. Science 276:111-113.
7. Walczak, H., M. A. Degli-Esposti, R. S. Johnson, P. J. Smolak, J. Y. Waugh, N. Boiani, M. S. Timour, M. J. Gerhart, K. A. Schooley, C. A. Smith, R. G. Goodwin and C. T. Rauch. 1997. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16:5386-5397.
8. Wu, G. S., T. F. Burns, E. R. McDonald, 3rd, W. Jiang, R. Meng, I. D. Krantz, G. Kao, D. D. Gan, J. Y. Zhou, R. Muschel, S. R. Hamilton, N. B. Spinner, S. Markowitz, G. Wu and W. S. el-Deiry. 1997. KILLER/DR5 is a DNA damage-inducible p53 -regulated death receptor gene. Nat Genet 17:141-143.
9. Chaudhary, P. M., M. Eby, A. Jasmin, A. Bookwalter, J. Murray and L. Hood. 1997. Death receptor 5, a new member of the TNF-R family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7:821-830.
10. Schneider, P., J. L. Bodmer, M. Thome, K. Hofmann, N. Holler and J. Tschopp. 1997. Characterization of two receptors for TRAIL. FEBS Lett 416:329-334.
11. Kimberley, F. C. and G. R. Screaton. 2004. Following a TRAIL: update on a ligand and its five receptors. Cell Res 14:359-372.
12. Wu, G. S., K. Kim and W. S. el-Deiry. 2000. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53 -tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol 465:143-151.
13. Burns, T. F., E. J. Bernhard and W. S. ElDeiry. 2001. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53 -dependent apoptosis in vivo. Oncogene 20:4601-4612.
14. Ganten, T M., T L. Haas, J. Sykora, H. Stahl, M. R. Sprick, S. C. Fas, A. Krueger, M. A. Weigand, A. Grosse-Wilde, W. Stremmel, P. H. Krammer and H. Walczak. 2004. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitization of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11 Suppl 1:S86-96.
15. Degli-Esposti, M. 1999. To die or not to die-the quest of the TRAIL receptors. J Leukoc Biol 65:535-542.
16. Wu, G. S., T. F. Burns, Y. Zhan, E. S. Alnemri and W. S. El-Deiry. 1999. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 59:2770-2775.
17. Schneider, P., D. Olson, A. Tardivel, B. Browning, A. Lugovskoy, D. Gong, M. Dobles, S. Hertig, K. Hofmann, H. Van Vlijmen, Y. M. Hsu, L. C. Burkly, J. Tschopp and T. S. Zheng. 2003. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 278:5444-5454.
18. Bodmer, J. L., N. Holler, S. Reynard, P. Vinciguerra, P. Schneider, P. Juo, J. Blenis and J. Tschopp. 2000. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2:241-243.
19. Kischkel, F. C., D. A. Lawrence, A. Chuntharapai, P. Schow, K. J. Kim and A. Ashkenazi. 2000. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12:611-620.
20. Sprick, M. R., M. A. Weigand, E. Rieser, C. T. Rauch, P. Juo, J. Blenis, P. H. Krammer and H. Walczak. 2000. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12:599-609.
21. Kischkel, F. C., D. A. Lawrence, A. Tinel, H. LeBlanc, A. Virmani, P. Schow, A. Gazdar, J. Blenis, D. Arnott and A. Ashkenazi. 2001. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276:46639-46646.
22. Sprick, M. R., E. Rieser, H. Stahl, A. Grosse-Wilde, M. A. Weigand and H. Walczak. 2002. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signaling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J 21:4520-4530.
23. Thorburn, A. 2004. Death receptor-induced cell killing. Cell Signal 16:139-144.
24. Griffith, T. S., C. T. Rauch, P. J. Smolak, J. Y. Waugh, N. Boiani, D. H. Lynch, C. A. Smith, R. G. Goodwin and M. Z. Kubin. 1999. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 162:2597-2605.
25. Muhlenbeck, F., P. Schneider, J. L. Bodmer, R. Schwenzer, A. Hauser, G. Schubert, P. Scheurich, D. Moosmayer, J. Tschopp and H. Wajant. 2000. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct crosslinking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem 275:32208-32213.
26. Kelley, R. F., K. Totpal, S. H. Lindstrom, M. Mathieu, K. Billeci, L. Deforge, R. Pai, S. G. Hymowitz and A. Ashkenazi. 2005. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol 280:2205-2212.
27. Wang, J., H. J. Chun, W. Wong, D. M. Spencer and M. J. Lenardo. 2001. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 98:13884-13888.
28. Wang, J., L. Zheng, A. Lobito, F. K. Chan, J. Dale, M. Sneller, X. Yao, J. M. Puck, S. E. Straus and M. J. Lenardo. 1999. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 98:47-58.
29. MacFarlane, M. 2003. TRAIL-induced signaling and apoptosis. Toxicol Lett 139:89-97.
30. L inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes. J Biol Chem 279:52824-52834.
31. Salvesen, G. S. and V. M. Dixit. 1999. Caspase activation: the induced-proximity model. Proc Natl Acad Sci USA 96:10964-10967.
32. Shi, Y. 2004. Caspase activation: revisiting the induced proximity model. Cell 117:855-858.
33. Tschopp, J., M. Irmler and M. Thome. 1998. Inhibition of fas death signals by FLIPs. Curr Opin Immunol 10:552-558.
34. Golks, A., D. Brenner, C. Fritsch, P. H. Krammer and I. N. Lavrik. 2005. c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 280:14507-14513.
35. Krueger, A., I. Schmitz, S. Baumann, P. H. Krammer and S. Kirchhoff. 2001. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 276:20633-20640.
36. Sharp, D. A., D. A. Lawrence and A. Ashkenazi. 2005. Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 280:19401-19409.
37. Zhang, L. and B. Fang. 2005. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228-237.
38. Peter, M. E. 2004. The flip side of FLIP. Biochem J 382:e1-e3.
39. Boatright, K. M., C. Deis, J. B. Denault, D. P. Sutherlin and G. S. Salvesen. 2004. Activation of caspases-8 and-10 by FLIPL. Biochem J 382:651-657.
40. Araujo, H., N. Danziger, J. Cordier, J. Glowinski and H. Chneiweiss. 1993. Characterization of PEA-15, a major substrate for protein kinase C in astrocytes. J Biol Chem 268:5911-5920.
41. Xiao, C., B. F. Yang, N. Asadi, F. Beguinot and C. Hao. 2002. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 277:25020-25025.
42. Ricci-Vitiani, L., F. Pedini, C. Mollinari, G. Condorelli, D. Bonci, A. Bez, A. Colombo, E. Parati, C. Peschle and R. De Maria. 2004. Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. J Exp Med 200:1257-1266.
43. Strasser, A. 2005. The role of BH3 -only proteins in the immune system. Nat Rev Immunol 5:189-200.
44. Sprick, M. R. and H. Walczak. 2004. The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta 1644:125-132.
45. Barnhart, B. C., E. C. Alappat and M. E. Peter. 2003. The CD95 type I/type II model. Semin Immunol 15:185-193.
46. Walczak, H., A. Bouchon, H. Stahl and P. H. Krammer. 2000. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2 -or Bcl-XL-overexpressing chemotherapy-resistant tumor cells. Cancer Res 60:3051-3057.
47. He, Q., Y. Huang and M. S. Sheikh. 2004. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and-deficient cells. Oncogene 23:2554-2558.
48. Shi, Y. 2004. Caspase activation, inhibition and reactivation: a mechanistic view. Protein Sci 13:1979-1987.
49. Harlin, H., S. B. Reffey, C. S. Duckett, T. Lindsten and C. B. Thompson. 2001. Characterization of XIAP-deficient mice. Mol Cell Biol 21:3604-3608.
50. Fulda, S., W. Wick, M. Weller and K. M. Debatin. 2002. Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8:808-815.
51. Li, L., R. M. Thomas, H. Suzuki, J. K. De Brabander, X. Wang and P. G. Harran. 2004. A small molecule Smac mimic potentiates TRAIL-and TNFalpha-mediated cell death. Science 305:1471-1474.
52. Suzuki, Y., Y. Imai, H. Nakayama, K. Takahashi, K. Takio and R. Takahashi. 2001. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 8:613-621.
53. Yang, Q. H., R. Church-Hajduk, J. Ren, M. L. Newton and C. Du. 2003. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev 17:1487-1496.
54. Zhang, H. G., J. Wang, X. Yang, H. C. Hsu and J. D. Mountz. 2004. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23:2009-2015.
55. Johnson, T. R., K. Stone, M. Nikrad, T. Yeh, W. X. Zong, C. B. Thompson, A. Nesterov and A. S. Kraft. 2003. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9negative or Bc1 -xl overexpressing cells. Oncogene 22:4953-4963.
56. Leverkus, M., M. R. Sprick, T. Wachter, T. Mengling, B. Baumann, E. Serfling, E. B. Brocker, M. Goebeler, M. Neumann and H. Walczak. 2003. Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol 23:777-790.
57. Ganten, T. M., R. Koschny, T. L. Haas, J. Sykora, M. Li-Weber, K. Herzer and H. Walczak. 2005. Proteasome inhibition sensitizes hepatocellular carcinoma cells but not human hepatocytes for TRAIL. Hepatology in press.
58. Sayers, T. J., A. D. Brooks, C. Y. Koh, W. Ma, N. Seki, A. Raziuddin, B. R. Blazar, X. Zhang, P. J. Elliott and W. J. Murphy. 2003. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102:303-310.
59. Breitschopf, K., A. M. Zeiher and S. Dimmeler. 2000. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem 275:21648-21652.
60. Li, B. and Q. P. Dou. 2000. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 97:3850-3855.
61. Zhang, X. D., X. Y. Zhang, C. P. Gray, T. Nguyen and P. Hersey. 2001. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by Smac/DIABLO release from mitochondria. Cancer Res 61:7339-7348.
62. Strater, J., U. Hinz, H. Walczak, G. Mechtersheimer, K. Koretz, C. Herfarth, P. Moller and T. Lehnert. 2002. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 8:3734-3740.
63. Spierings, D. C., E. G. de Vries, W Timens, H. J. Groen, H. M. Boezen and S. de Jong. 2003. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 9:3397-3405.
64. Wistuba, II, C. Behrens, A. K. Virmani, S. Milchgrub, S. Syed, S. Lam, B. Mackay, J. D. Minna and A. F. Gazdar. 1999. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 59:1973-1979.
65. Emi, M., Y. Fujiwara, T. Nakajima, E. Tsuchiya, H. Tsuda, S. Hirohashi, Y. Maeda, K. Tsuruta, M. Miyaki and Y. Nakamura. 1992. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer and lung cancer. Cancer Res 52:5368-5372.
66. Kagan, J., J. Stein, R. J. Babaian, Y. S. Joe, L. L. Pisters, A. B. Glassman, A. C. von Eschenbach and P. Troncoso. 1995. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 11:2121-2126.
67. Yaremko, M. L., C. Kutza, J. Lyzak, R. Mick, W. M. Recant and C. A. Westbrook. 1996. Loss of heterozygosity from the short arm of chromosome 8 is associated with invasive behavior in breast cancer. Genes Chromosomes Cancer 16:189-195.
68. Shin, M. S., H. S. Kim, S. H. Lee, W. S. Park, S. Y. Kim, J. Y. Park, J. H. Lee, S. K. Lee, S. N. Lee, S. S. Jung, J. Y. Han, H. Kim, J. Y. Lee and N. J. Yoo. 2001. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 61:4942-4946.
69. Seitz, S., P. Wassmuth, J. Fischer, A. Nothnagel, B. Jandrig, P. M. Schlag and S. Scherneck. 2002. Mutation analysis and mRNA expression of trail-receptors in human breast cancer. Int J Cancer 102:117-128.
70. Jeng, Y. M. and H. C. Hsu. 2002. Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma. Cancer Lett 181:205-208.
71. Lee, S. H., M. S. Shin, H. S. Kim, H. K. Lee, W. S. Park, S. Y. Kim, J. H. Lee, S. Y. Han, J. Y. Park, R. R. Oh, C. S. Kang, K. M. Kim, J. J. Jang, S. W. Nam, J. Y. Lee and N. J. Yoo. 2001. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 20:399-403.
72. Lee, S. H., M. S. Shin, H. S. Kim, H. K. Lee, W. S. Park, S. Y. Kim, J. H. Lee, S. Y. Han, J. Y. Park, R. R. Oh, J. J. Jang, J. Y. Han, J. Y. Lee and N. J. Yoo. 1999. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 59:5683-5686.
73. Wu, W G., J. C. Soria, L. Wang, B. L. Kemp and L. Mao. 2000. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer. Anticancer Res 20:4525-4529.
74. Fisher, M. J., A. K. Virmani, L. Wu, R. Aplenc, J. C. Harper, S. M. Powell, T. R. Rebbeck, D. Sidransky, A. F. Gazdar and W. S. El-Deiry. 2001. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 7:1688-1697.
75. Dechant, M. J., J. Fellenberg, C. G. Scheuerpflug, V. Ewerbeck and K. M. Debatin. 2004. Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int J Cancer 109:661-667.
76. Shivapurkar, N., S. Toyooka, K. O. Toyooka, J. Reddy, K. Miyajima, M. Suzuki, H. Shigematsu, T. Takahashi, G. Parikh, H. I. Pass, P. M. Chaudhary and A. F. Gazdar. 2004. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 109:786-792.
77. Walczak, H. and P. H. Krammer. 2000. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256:58-66.
78. Wajant, H., K. Pfizenmaier and P. Scheurich. 2002. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 7:449-459.
79. Wu, X. X., O. Ogawa and Y. Kakehi. 2004. TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm 67:365-383.
80. Shankar, S. and R. K. Srivastava. 2004. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Update 7:139-156.
81. Wajant, H., J. Gerspach and K. Pfizenmaier. 2005. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 16:55-76.
82. Ashkenazi, A., R. C. Pai, S. Fong, S. Leung, D. A. Lawrence, S. A. Marsters, C. Blackie, L. Chang, A. E. McMurtrey, A. Hebert, L. DeForge, I. L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh and R. H. Schwall. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162.
83. Walczak, H., R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R. G. Goodwin, C. T Rauch, J. C. Schuh and D. H. Lynch. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163.
84. Lawrence, D., Z. Shahrokh, S. Marsters, K. Achilles, D. Shih, B. Mounho, K. Hillan, K. Totpal, L. DeForge, P. Schow, J. Hooley, S. Sherwood, R. Pai, S. Leung, L. Khan, B. Gliniak, J. Bussiere, C. A. Smith, S. S. Strom, S. Kelley, J. A. Fox, D. Thomas and A. Ashkenazi. 2001. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383-385.
85. Griffith, T. S., W. A. Chin, G. C. Jackson, D. H. Lynch and M. Z. Kubin. 1998. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161:2833-2840.
86. Gazitt, Y. 1999. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13:1817-1824.
87. Leverkus, M., M. Neumann, T. Mengling, C. T. Rauch, E. B. Brocker, P. H. Krammer and H. Walczak. 2000. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60:553-559.
88. Atkins, G. J., S. Bouralexis, A. Evdokiou, S. Hay, A. Labrinidis, A. C. Zannettino, D. R. Haynes and D. M. Findlay. 2002. Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone 31:448-456.
89. Zhang, X. D., T. Nguyen, W. D. Thomas, J. E. Sanders and P. Hersey. 2000. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 482:193-199.
90. Wu, X. X., Y. Kakehi, Y. Mizutani, T. Kamoto, H. Kinoshita, Y. Isogawa, T. Terachi and O. Ogawa. 2002. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int J Oncol 20:949-954.
91. Walczak, H., R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R. G. Goodwin, C. T Rauch, J. C. Schuh and D. H. Lynch. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163.
92. Jo, M., T H. Kim, D. W. Seol, J. E. Esplen, K. Dorko, T. R. Billiar and S. C. Strom. 2000. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6:564-567.
93. Ichikawa, K., W. Liu, L. Zhao, Z. Wang, D. Liu, T. Ohtsuka, H. Zhang, J. D. Mountz, W. J. Koopman, R. P. Kimberly and T Zhou. 2001. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7:954-960.
94. Hao, C., J. H. Song, B. Hsi, J. Lewis, D. K. Song, K. C. Petruk, D. L. Tyrrell and N. M. Kneteman. 2004. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 64:8502-8506.
95. Qin, J., V. Chaturvedi, B. Bonish and B. J. Nickoloff. 2001. Avoiding premature apoptosis of normal epidermal cells. Nat Med 7:385-386.
96. Nitsch, R., I. Bechmann, R. A. Deisz, D. Haas, T. N. Lehmann, U. Wendling and F. Zipp. 2000. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356:827-828.
97. Smyth, M. J., K. Takeda, Y. Hayakawa, J. J. Peschon, M. R. van den Brink and H. Yagita. 2003. Nature's TRAIL-on a path to cancer immunotherapy. Immunity 18:1-6.
98. Yagita, H., K. Takeda, Y. Hayakawa, M. J. Smyth and K. Okumura. 2004. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95:777-783.
99. Higuchi, H., A. Grambihler, A. Canbay, S. F. Bronk and G. J. Gores. 2004. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem 279:51-60.
100. Bremer, E., D. Samplonius, B. J. Kroesen, L. van Genne, L. de Leij and W. Helfrich. 2004. Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia 6:636-645.
101. Bremer, E., D. F. Samplonius, M. Peipp, L. van Genne, B. J. Kroesen, G. H. Fey, M. Gramatzki, L. F. de Leij and W. Helfrich. 2005. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 65:3380-3388.
102. Motoki, K., E. Mori, A. Matsumoto, M. Thomas, T. Tomura, R. Humphreys, V. Albert, M. Muto, H. Yoshida, M. Aoki, T. Tamada, R. Kuroki, I. Ishida, C. F. Ware and S. Kataoka. 2005. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 11:3126-3135.
103. Mori, E., M. Thomas, K. Motoki, K. Nakazawa, T. Tahara, K. Tomizuka, I. Ishida and S. Kataoka. 2004. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ 11:203-207.
104. Takeda, K., N. Yamaguchi, H. Akiba, Y Kojima, Y. Hayakawa, J. E. Tanner, T. J. Sayers, N. Seki, K. Okumura, H. Yagita and M. J. Smyth. 2004. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199:437-448.
105. Buchsbaum, D. J., T. Zhou, W. E. Grizzle, P. G. Oliver, C. J. Hammond, S. Zhang, M. Carpenter and A. F. LoBuglio. 2003. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 9:3731-3741.
106. Ichikawa, K., W Liu, M. Fleck, H. Zhang, L. Zhao, T. Ohtsuka, Z. Wang, D. Liu, J. D. Mountz, M. Ohtsuki, W. J. Koopman, R. Kimberly and T. Zhou. 2003. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 171:1061-1069.
107. Chuntharapai, A., K. Dodge, K. Grimmer, K. Schroeder, S. A. Marsters, H. Koeppen, A. Ashkenazi and K. J. Kim. 2001. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166:4891-4898.
108. Pukac, L., P. Kanakaraj, R. Humphreys, R. Alderson, M. Bloom, C. Sung, T. Riccobene, R. Johnson, M. Fiscella, A. Mahoney, J. Carrell, E. Boyd, X. T. Yao, L. Zhang, L. Zhong, A. von Kerczek, L. Shepard, T. Vaughan, B. Edwards, C. Dobson, T. Salcedo and V. Albert. 2005. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92:1430-1441.
109. Garber, K. 2005. New apoptosis drugs face critical test. Nat Biotechnol 23:409-411.
110. Norris, J. S., M. L. Hyer, C. Voelkel-Johnson, S. L. Lowe, S. Rubinchik and J. Y. Dong. 2001. The use of Fas ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther 1:123-136.
111. Griffith, T. S., R. D. Anderson, B. L. Davidson, R. D. Williams and T. L. Ratliff. 2000. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 165:2886-2894.
112. Voelkel-Johnson, C., D. L. King and J. S. Norris. 2002. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 9:164-172.
113. Yamashita, Y., M. Shimada, S. Tanaka, M. Okamamoto, J. Miyazaki and K. Sugimachi. 2002. Electroporation-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L gene therapy for hepatocellular carcinoma. Hum Gene Ther 13:275-286.
114. Griffith, T S. and E. L. Broghammer. 2001. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 4:257-266.
115. Lee, J., M. Hampl, P. Albert and H. A. Fine. 2002. Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 4:312-323.
116. Kagawa, S., C. He, J. Gu, P. Koch, S. J. Rha, J. A. Roth, S. A. Curley, L. C. Stephens and B. Fang. 2001. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 61:3330-3338.
117. Armeanu, S., U. M. Lauer, I. Smirnow, M. Schenk, T. S. Weiss, M. Gregor and M. Bitzer. 2003. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 63:2369-2372.
118. Lin, T., J. Gu, L. Zhang, X. Huang, L. C. Stephens, S. A. Curley and B. Fang. 2002. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 62:3620-3625.
119. Lin, T., X. Huang, J. Gu, L. Zhang, J. A. Roth, M. Xiong, S. A. Curley, Y. Yu, K. K. Hunt and B. Fang. 2002. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 21:8020-8028.
120. Belka, C., Jendrossek, M. Pruschy, S. Vink, M. Verheij and W. Budach. 2004. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys 58:542-554.
121. Taniai, M., A. Grambihler, H. Higuchi, N. Werneburg, S. F. Bronk, D. J. Farrugia, S. H. Kaufmann and G. J. Gores. 2004. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 64:3517-3524.
122. Verhagen, A. M., E. J. Coulson and D. L. Vaux. 2001. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol 2:3009.1-3009.10.
123. Ravi, R., G. C. Bedi, L. W. Engstrom, Q. Zeng, B. Mookerjee, C. Gelinas, E. J. Fuchs and A. Bedi. 2001. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 3:409-416.
124. Wajant, H. 2004. TRAIL and NFkappaB signaling-a complex relationship. Vitam Horm 67:101-132.
125. Larribere, L., M. Khaled, S. Tartare-Deckert, R. Busca, F. Luciano, K. Bille, G. Valony, A. Eychene, P. Auberger, J. P. Ortonne, R. Ballotti and C. Bertolotto. 2004. P13K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ 11:1084-1091.
126. Wang, Q., X. Wang, A. Hernandez, M. R. Hellmich, Z. Gatalica and B. M. Evers. 2002. Regulation of TRAIL expression by the phosphatidylinositol 3 -kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem 277:36602-36610.
127. Panka, D. J., T. Mano, T. Suhara, K. Walsh and J. W. Mier. 2001. Phosphatidylinositol-3 kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 276:6893-6896.
128. Whang, Y. E., X. J. Yuan, Y. Liu, S. Majumder and T. D. Lewis. 2004. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor. Vitam Horm 67:409-426.
129. Harper, N., M. A. Hughes, S. N. Farrow, G. M. Cohen and M. MacFarlane. 2003. Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling. J Biol Chem 278:44338-44347.
130. Keane, M. M., S. A. Ettenberg, M. M. Nau, E. K. Russell and S. Lipkowitz. 1999. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59:734-741.
131. Wen, J., N. Ramadevi, D. Nguyen, C. Perkins, E. Worthington and K. Bhalla. 2000. Antileukemic drugs increase death receptor 5 levels and enhance apo-2L-induced apoptosis of human acute leukemia cells. Blood 96:3900-3906.
132. Chinnaiyan, A. M., U. Prasad, S. Shankar, D. A. Hamstra, M. Shanaiah, T. L. Chenevert, B. D. Ross and A. Rehemtulla. 2000. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 97:1754-1759.
133. Dejosez, M., U. Ramp, C. Mahotka, A. Krieg, H. Walczak, H. E. Gabbert and C. D. Gerharz. 2000. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ 7:1127-1136.
134. Nagane, M., G. Pan, J. J. Weddle, V M. Dixit, W. K. Cavenee and H. J. Huang. 2000. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60:847-853.
135. Belka, C., B. Schmid, P. Marini, E. Durand, J. Rudner, H. Faltin, M. Bamberg, K. Schulze-Osthoff and W. Budach. 2001. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 20:2190-2196.
136. Gibson, E. M., E. S. Henson, N. Haney, J. Villanueva and S. B. Gibson. 2002. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Res 62:488-496.
137. Marini, P., A. Schmid, V Jendrossek, H. Faltin, P. T. Daniel, W. Budach and C. Belka. 2005. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 5:5.
138. Sun, S. Y., P. Yue, W. K. Hong and R. Lotan. 2000. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1 -adamantyl)-4 -hydroxyphenyl]-2 -naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 60:7149-7155.
139. Di Pietro, R., P. Secchiero, R. Rana, D. Gibellini, G. Visani, K. Bemis, L. Zamai, S. Miscia and G. Zauli. 2001. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 97:2596-2603.
140. Evdokiou, A., S. Bouralexis, G. J. Atkins, F. Chai, S. Hay, M. Clayer and D. M. Findlay. 2002. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 99:491-504.
141. Mitsiades, N., C. S. Mitsiades, V. Poulaki, K. C. Anderson and S. P. Treon. 2002. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 99:2162-2171.
142. Wuchter, C., D. Krappmann, Z. Cai, V Ruppert, C. Scheidereit, B. Dorken, W. D. Ludwig and L. Karawajew. 2001. in vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia 15:921-928.
143. Bin, L., X. Li, L. G. Xu and H. B. Shu. 2002. The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Lett 510:37-40.
144. Muhlethaler-Mottet, A., K. Balmas, K. Auderset, J. M. Joseph and N. Gross. 2003. Restoration of TRAIL-induced apoptosis in a caspase-8 -deficient neuroblastoma cell line by stable re-expression of caspase-8. Ann NYAcad Sci 1010:195-199.
145. Teitz, T., T. Wei, M. B. Valentine, E. F. Vanin, J. Grenet, V. A. Valentine, F. G. Behm, A. T. Look, J. M. Lahti and V. J. Kidd. 2000. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6:529-535.
146. Hopkins-Donaldson, S., A. Ziegler, S. Kurtz, C. Bigosch, D. Kandioler, C. Ludwig, U. Zangemeister-Wittke and R. Stahel. 2003. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 10:356-364.
147. Hopkins-Donaldson, S., J. L. Bodmer, K. B. Bourloud, C. B. Brognara, J. Tschopp and N. Gross. 2000. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 60:4315-4319.
148. Fulda, S., M. U. Kufer, E. Meyer, F. van Valen, B. Dockhorn-Dworniczak and K. M. Debatin. 2001. Sensitization for death receptor-or drug-induced apoptosis by reexpression of caspase-8 through de-methylation or gene transfer. Oncogene 20:5865-5877.
149. Altucci, L. and H. Gronemeyer. 2002. Decryption of the retinoid death code in leukemia. J Clin Immunol 22:117-123.
150. Nebbioso, A., N. Clarke, E. Voltz, E. Germain, C. Ambrosino, P. Bontempo, R. Alvarez, E. M. Schiavone, F. Ferrara, F. Bresciani, A. Weisz, A. R. de Lera, H. Gronemeyer and L. Altucci. 2005. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11:77-84.
151. Insinga, A., S. Monestiroli, S. Ronzoni, V. Gelmetti, F. Marchesi, A. Viale, L. Altucci, C. Nervi, S. Minucci and P. G. Pelicci. 2005. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71-76.
152. Kayagaki, N., N. Yamaguchi, M. Nakayama, H. Eto, K. Okumura and H. Yagita. 1999. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 189:1451-1460.
153. Ruiz-Ruiz, C. and A. Lopez-Rivas. 2002. Mitochondria-dependent and-independent mechanisms in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumor cells. Biochem J 365:825-832.
154. Song, K., Y. Chen, R. Goke, A. Wilmen, C. Seidel, A. Goke and B. Hilliard. 2000. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 191:1095-1104.
155. Martinez-Lorenzo, M. J., M. A. Alava, S. Gamen, K. J. Kim, A. Chuntharapai, A. Pineiro, J. Naval and A. Anel. 1998. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol 28:2714-2725.
156. Jeremias, I., I. Herr, T. Boehlerand K. M. Debatin. 1998. TRAIL/Apo-2 -ligand-induced apoptosis in human T cells. Eur J Immunol 28:143-152.
157. Zhang, X. R., L. Y. Zhang, S. Devadas, L. Li, A. D. Keegan and Y. F. Shi. 2003. Reciprocal expression of TRAIL and CD95L in Th1 and Th2 cells: role of apoptosis in T helper subset differentiation. Cell Death Differ 10:203-210.
158. Janssen, E. M., N. M. Droin, E. E. Lemmens, M. J. Pinkoski, S. J. Bensinger, B. D. Ehst, T. S. Griffith, D. R. Green and S. P. Schoenberger. 2005. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434:88-93.
159. Smyth, M. J., E. Cretney, K. Takeda, R. H. Wiltrout, L. M. Sedger, N. Kayagaki, H. Yagita and K. Okumura. 2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193:661-670.
160. Takeda, K., M. J. Smyth, E. Cretney, Y. Hayakawa, N. Yamaguchi, H. Yagita and K. Okumura. 2001. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol 214:194-200.
161. Takeda, K., Y. Hayakawa, M. J. Smyth, N. Kayagaki, N. Yamaguchi, S. Kakuta, Y. Iwakura, H. Yagita and K. Okumura. 2001. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7:94100.
162. Trinchieri, G. 1989. Biology of natural killer cells. Adv Immunol 47:187-376.
163. Takeda, K., E. Cretney, Y. Hayakawa, T. Ota, H. Akiba, K. Ogasawara, H. Yagita, K. Kinoshita, K. Okumura and M. J. Smyth. 2005. TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood 105:2082-2089.
164. Zamai, L., M. Ahmad, I. M. Bennett, L. Azzoni, E. S. Alnemri and B. Perussia. 1998. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 188:2375-2380.
165. Miller, F. R., B. E. Miller and G. H. Heppner. 1983. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3:22-31.
166. Aslakson, C. J. and F. R. Miller. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52:1399-1405.
167. Cretney, E., K. Takeda, H. Yagita, M. Glaccum, J. J. Peschon and M. J. Smyth. 2002. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168:1356-1361.
168. Davis, J. E., V. R. Sutton, M. J. Smyth and J. A. Trapani. 2000. Dependence of granzyme B-mediated cell death on a pathway regulated by Bcl-2 or its viral homolog, BHRF1. Cell Death Differ 7:973-983.
169. Smyth, M. J., N. Y. Crowe and D. I. Godfrey. 2001. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 13:459-463.
170. Street, S. E., E. Cretney and M. J. Smyth. 2001. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97:192-197.
171. Sedger, L. M., M. B. Glaccum, J. C. Schuh, S. T. Kanaly, E. Williamson, N. Kayagaki, T. Yun, P. Smolak, T. Le, R. Goodwin and B. Gliniak. 2002. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 32:2246-2254.
172. Takeda, K., M. J. Smyth, E. Cretney, Y. Hayakawa, N. Kayagaki, H. Yagita and K. Okumura. 2002. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 195:161-169.
173. Yue, H. H., G. E. Diehl and A. Winoto. 2005. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ 12:94-97.
174. Katze, M. G., Y. He and M. Gale, Jr. 2002. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2:675-687.
175. Biron, C. A. 2001. Interferons alpha and beta as immune regulators-a new look. Immunity 14:661-664.
176. Griffith, T. S., S. R. Wiley, M. Z. Kubin, L. M. Sedger, C. R. Maliszewski and N. A. Fanger. 1999. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189:1343-1354.
177. Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman and R. D. Schreiber. 1998. How cells respond to interferons. Annu Rev Biochem 67:227-264.
178. Chawla-Sarkar, M., J. A. Bauer, J. A. Lupica, B. H. Morrison, Z. Tang, R. K. Oates, A. Almasan, J. A. DiDonato, E. C. Borden and D. J. Lindner. 2003. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem 278:39461-39469.
179. Chen, Q., B. Gong, A. S. Mahmoud-Ahmed, A. Zhou, E. D. Hsi, M. Hussein and A. Almasan. 2001. Apo2L/TRAIL and Bcl-2 -related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 98:2183-2192.
180. Chawla-Sarkar, M., D. W. Leaman and E. C. Borden. 2001. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2l induction in melanoma cell lines. Clin Cancer Res 7:1821-1831.
181. Morrison, B. H., J. A. Bauer, J. Hu, R. W Grane, A. M. Ozdemir, M. Chawla-Sarkar, B. Gong, A. Almasan, D. V. Kalvakolanu and D. J. Lindner. 2002. Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics. Oncogene 21:1882-1889.
182. Leaman, D. W., M. Chawla-Sarkar, K. Vyas, M. Reheman, K. Tamai, S. Toji and E. C. Borden. 2002. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem 277:28504-28511.
183. Wang, S. H., E. Mezosi, J. M. Wolf, Z. Cao, S. Utsugi, P. G. Gauger, G. M. Doherty and J. R. Baker, Jr. 2004. IFN-gamma sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression. Oncogene 23:928-935.
184. Shigeno, M., K. Nakao, T. Ichikawa, K. Suzuki, A. Kawakami, S. Abiru, S. Miyazoe, Y. Nakagawa, H. Ishikawa, K. Hamasaki, K. Nakata, N. Ishii and K. Eguchi. 2003. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene 22:1653-1662.
185. Kumar-Sinha, C., S. Varambally, A. Sreekumar and A. M. Chinnaiyan. 2002. Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem 277:575-585.
186. Sedger, L. M., D. M. Shows, R. A. Blanton, J. J. Peschon, R. G. Goodwin, D. Cosman and S. R. Wiley. 1999. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 163:920-926.
187. Strater, J., H. Walczak, T. Pukrop, L. Von Muller, C. Hasel, M. Kornmann, T. Mertens and P. Moller. 2002. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. Gastroenterology 122:659-666.
188. Clarke, P., S. M. Meintzer, S. Gibson, C. Widmann, T. P. Garrington, G. L. Johnson and K. L. Tyler. 2000. Reovirus-induced apoptosis is mediated by TRAIL. J Virol 74:8135-8139.
189. Benedict, C. A. 2003. Viruses and the TNF-related cytokines, an evolving battle. Cytokine Growth Factor Rev 14:349-357.
190. Sato, K., S. Hida, H. Takayanagi, T. Yokochi, N. Kayagaki, K. Takeda, H. Yagita, K. Okumura, N. Tanaka, T. Taniguchi and K. Ogasawara. 2001. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 31:3138-3146.
191. Fulda, S. and K. M. Debatin. 2002. IFN-gamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21:2295-2308.
192. Washburn, B., M. A. Weigand, A. GrosseWilde, M. Janke, H. Stahl, E. Rieser, M. R. Sprick, V. Schirrmacher and H. Walczak. 2003. TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol 170:1814-1821.
193. Wurzer, W. J., C. Ehrhardt, S. Pleschka, F. Berberich-Siebelt, T. Wolff, H. Walczak, O. Planz and S. Ludwig. 2004. NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation. J Biol Chem 279:30931-30937.
194. Raftery, M. J., M. Schwab, S. M. Eibert, Y. Samstag, H. Walczak and G. Schonrich. 2001. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity 15:997-1009.
195. Fugier-Vivier, I., C. Servet-Delprat, P. Rivailler, M. C. Rissoan, Y. J. Liu and C. Rabourdin-Combe. 1997. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J Exp Med 186:813-823.
196. Vidalain, P. O., O. Azocar, B. Lamouille, A. Astier, C. Rabourdin-Combe and C. Servet-Delprat. 2000. Measles virus induces functional TRAIL production by human dendritic cells. J Virol 74:556-559.
197. Katsikis, P. D., M. E. Garcia-Ojeda, J. F. Torres-Roca, I. M. Tijoe, C. A. Smith and L. A. Herzenberg. 1997. Interleukin-1 beta converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection. TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection. J Exp Med 186:1365-1372.
198. Miura, Y., N. Misawa, N. Maeda, Y. Inagaki, Y. Tanaka, M. Ito, N. Kayagaki, N. Yamamoto, H. Yagita, H. Mizusawa and Y. Koyanagi. 2001. Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1 -infected hu-PBL-NOD-SCID mice. J Exp Med 193:651-660.
199. Miura, Y., N. Misawa, Y. Kawano, H. Okada, Y. Inagaki, N. Yamamoto, M. Ito, H. Yagita, K. Okumura, H. Mizusawa and Y. Koyanagi. 2003. Tumor necrosis factor-related apoptosis-inducing ligand induces neuronal death in a murine model of HIV central nervous system infection. Proc Natl Acad Sci USA 100:2777-2782.
200. Liabakk, N. B., A. Sundan, S. Torp, P. Aukrust, S. S. Froland and T. Espevik. 2002. Development, characterization and use of monoclonal antibodies against sTRAIL: measurement of sTRAIL by ELISA. J Immunol Methods 259:119-128.
201. Han, L. H., W S. Sun, C. H. Ma, L. N. Zhang, S. X. Liu, Q. Zhang, L. F. Gao and Y. H. Chen. 2002. Detection of soluble TRAIL in HBV infected patients and its clinical implications. World J Gastroenterol 8:1077-1080.
202. Diehl, G. E., H. H. Yue, K. Hsieh, A. A. Kuang, M. Ho, L. A. Morici, L. L. Lenz, D. Cado, L. W. Riley and A. Winoto. 2004. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21:877-889.
203. Zheng, S. J., J. Jiang, H. Shen and Y. H. Chen. 2004. Reduced apoptosis and ameliorated listeriosis in TRAIL-null mice. J Immunol 173:5652-5658.
204. -/-mice. Nat Immunol 4:255-260.
205. Liu, Z., X. Xu, H. C. Hsu, A. Tousson, P. A. Yang, Q. Wu, C. Liu, S. Yu, H. G. Zhang and J. D. Mountz. 2003. CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest 112:1332-1341.
206. Miranda-Carus, M. E., A. Balsa, M. Benito-Miguel, C. P. De Ayala and E. Martin-Mola. 2004. Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active. Arthritis Rheum 50:2786-2793.
207. Perlman, H., N. Nguyen, H. Liu, J. Eslick, S. Esser, K. Walsh, T. L. Moore and R. M. Pope. 2003. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3. Arthritis Rheum 48:3096-3101.
208. Morel, J., R. Audo, M. Hahne and B. Combe. 2005. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphati-dylinositol 3 -kinase/Akt. J Biol Chem 280:15709-15718.
209. Hilliard, B., A. Wilmen, C. Seidel, T. S. Liu, R. Goke and Y. Chen. 2001. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol 166:1314-1319.
210. Aktas, O., A. Smorodchenko, S. Brocke, C. Infante-Duarte, U. S. Topphoff, J. Vogt, T. Prozorovski, S. Meier, V. Osmanova, E. Pohl, I. Bechmann, R. Nitsch and F. Zipp. 2005. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46:421-432.
211. Mezosi, E., S. H. Wang, S. Utsugi, L. Bajnok, J. D. Bretz, P. G. Gauger, N. W. Thompson and J. R. Baker, Jr. 2004. Interleukin-1beta and tumor necrosis factor (TNF)-alpha sensitize human thyroid epithelial cells to TNF-related apoptosis-inducing ligand-induced apoptosis through increases in procaspase-7 and bid, and the down-regulation of p44/42 mitogen-activated protein kinase activity. J Clin Endocrinol Metab 89:250-257.
212. Bretz, J. D., E. Mezosi, T. J. Giordano, P. G. Gauger, N. W. Thompson and J. R. Baker, Jr. 2002. Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Cell Death Differ 9:274-286.
213. Stassi, G. and R. De Maria. 2002. Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat Rev Immunol 2:195-204.
214. Cretney, E., A. P. Uldrich, S. P. Berzins, A. Strasser, D. I. Godfrey and M. J. Smyth. 2003. Normal thymocyte negative selection in TRAIL-deficient mice. J Exp Med 198:491-496.
215. Simon, A. K., O. Williams, J. Mongkolsapaya, B. Jin, X. N. Xu, H. Walczak and G. R. Screaton. 2001. Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes. Proc Natl Acad Sci USA 98:5158-5163.
216. Newton, K., A. W. Harris, M. L. Bath, K. G. C. Smith and A. Strasser. 1998. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J 17:706-718.
217. Corazza, N., G. Brumatti, S. Jakob, A. Villunger and T. Brunner. 2004. TRAIL and thymocyte apoptosis: not so deadly? Cell Death Differ 11(Suppl 2):S213-215.
218. van den Brink, M. R. and S. J. Burakoff. 2002. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2:273-281.
219. Bleakley, M. and S. R. Riddell. 2004. Molecules and mechanisms of the graftversus-leukaemia effect. Nat Rev Cancer 4:371-380.
220. Schmaltz, C., O. Alpdogan, B. J. Kappel, S. J. Muriglan, J. A. Rotolo, J. Ongchin, L. M. Willis, A. S. Greenberg, J. M. Eng, J. M. Crawford, G. F. Murphy, H. Yagita, H. Walczak, J. J. Peschon and M. R. Van Den Brink. 2002. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 8:1433-1437.
221. Plasilova, M., J. Zivny, J. Jelinek, R. Neuwirtova, J. Cermak, E. Necas, L. Andera and T. Stopka. 2002. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 16:67-73.
222. Ruggeri, L., M. Capanni, M. Casucci, I. Volpi, A. Tosti, K. Perruccio, E. Urbani, R. S. Negrin, M. F. Martelli and A. Velardi. 1999. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94:333-339.
223. Sato, K., T. Nakaoka, N. Yamashita, H. Yagita, H. Kawasaki, C. Morimoto, M. Baba and T. Matsuyama. 2005. TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J Immunol 174:4025-4033.
224. Martin, J. H., A. Potthoff, S. Ledig, M. Cornberg, O. Jandl, M. P. Manns, S. Kubicka, P. Flemming, C. Athmann, W. Beil and S. Wagner. 2004. Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis. Helicobacter 9:371-386.
225. Koornstra, J. J., J. H. Kleibeuker, C. M. van Geelen, F. E. Rijcken, H. Hollema, E. G. de Vries and S. de Jong. 2003. Expression of TRAIL (TNF-related apopto-sis-inducing ligand) and its receptors in normal colonic mucosa, adenomas and carcinomas. J Pathol 200:327-335.
226. Tanaka, S., K. Sugimachi, K. Shirabe, M. Shimada and J. R. Wands. 2000. Expression and antitumor effects of TRAIL in human cholangiocarcinoma. Hepatology 32:523-527.
227. Spierings, D. C., E. G. de Vries, E. Vellenga, F. A. van den Heuvel, J. J. Koornstra, J. Wesseling, H. Hollema and S. de Jong. 2004. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 52:821-831.
228. Hasel, C., S. Durr, B. Rau, J. Strater, R. M. Schmid, H. Walczak, M. G. Bachem and P. Moller. 2003. In chronic pancreatitis, widespread emergence of TRAIL receptors in epithelia coincides with neoexpression of TRAIL by pancreatic stellate cells of early fibrotic areas. Lab Invest 83:825-836.
229. Satoh, K., K. Kaneko, M. Hirota, A. Masamune, A. Satoh and T. Shimosegawa. 2001. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas 23:251-258.
230. Rieger, J., H. Ohgaki, P. Kleihues and M. Weller. 1999. Human astrocytic brain tumors express AP02L/TRAIL. Acta Neuropathol (Berl) 97:1-4.
231. Dorr, J., S. Waiczies, U. Wendling, B. Seeger and F. Zipp. 2002. Induction of TRAIL-mediated glioma cell death by human T cells. J Neuroimmunol 122:117-124.
232. Herrnring, C., T. Reimer, U. Jeschke, J. Makovitzky, K. Kruger, B. Gerber, D. Kabelitz and K. Friese. 2000. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol 113:189-194.
233. Arts, H. J., S. de Jong, H. Hollema, K. ten Hoor, A. G. van der Zee and E. G. de Vries. 2004. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol Oncol 92:794-800.
234. Mitsiades, N., V. Poulaki, S. Tseleni-Balafouta, D. A. Koutras and I. Stamenkovic. 2000. Thyroid carcinoma cells are resistant to FAS-mediated apoptossi but sensitive tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 60:4122-4129.
235. Yamamoto, T., H. Nagano, M. Sakon, H. Wada, H. Eguchi, M. Kondo, B. Damdinsuren, H. Ota, M. Nakamura, S. Marubashi, A. Miyamoto, K. Dono, K. Umeshita, S. Nakamori, H. Yagita and M. Monden. 2004. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5 -fluorouracil against hepatocellular carcinoma. Clin Cancer Res 10:7884-7895.
236. Chen, X. P., S. Q. He, H. P. Wang, Y. Z. Zhao and W. G. Zhang. 2003. Expression of TNF-related apoptosis-inducing ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. World J Gastroenterol 9:2433-2440.
237. Mitsiades, N., V. Poulaki, C. Mitsiades and M. Tsokos. 2001. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res 61:2704-2712.
238. Ryu, H. S., K. H. Chang, S. J. Chang, M. S. Kim, H. J. Joo and K. S. Oh. 2000. Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer. Int J Gynecol Cancer 10:417-424.
239. Ozawa, F., H. Friess, J. Kleeff, Z. W. Xu, A. Zimmermann, M. S. Sheikh and M. W. Buchler. 2001. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 163:71-81.
240. Liao, Q., H. Friess, J. Kleeff and M. W. Buchler. 2001. Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer. Anticancer Res 21:3153-3159.
241. Wu, X. X., Y. Kakehi, Y. Mizutani, H. Nishiyama, T. Kamoto, Y. Megumi, N. Ito and O. Ogawa. 2003. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer 104:409-417.
242. Qin, J. Z., P. Bacon, J. Panella, L. A. Sitailo, M. F. Denning and B. J. Nickoloff. 2004. Low-dose UV-radiation sensitizes keratinocytes to TRAIL-induced apoptosis. J Cell Physiol 200:155-166.
243. Kothny-Wilkes, G., D. Kulms, B. Poppelmann, T. A. Luger, M. Kubin and T. Schwarz. 1998. Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 273:29247-29253.
244. Taimr, P., H. Higuchi, E. Kocova, R. A. Rippe, S. Friedman and G. J. Gores. 2003. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 37:87-95.
245. Nesterov, A., Y. Ivashchenko and A. S. Kraft. 2002. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 21:1135-1140.
246. Li, J. H., N. C. Kirkiles-Smith, J. M. McNiff and J. S. Pober. 2003. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 171:1526-1533.
247. Kondo, K., S. Yamasaki, T. Sugie, N. Teratani, T. Kan, M. Imamura and Y. Shimada. 2005. Cisplatin-dependent up-regulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma. Int J Cancer in press.
248. Ren, Y. G., K. W. Wagner, D. A. Knee, P. Aza-Blanc, M. Nasoff and Q. L. Deveraux. 2004. Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell 15:5064-5074.
249. Fan, Q. L., W. Y. Zou, L. H. Song and W. Wei. 2005. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo. Cancer Chemother Pharmacol 55:189-196.
250. Roa, W. H., H. Chen, D. Fulton, S. Gulavita, A. Shaw, J. Th'ng, M. Farr-Jones, R. Moore and K. Petruk. 2003. X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells. Clin Invest Med 26:231-242.
251. Hernandez, A., Q. Wang, S. A. Schwartz and B. M. Evers. 2001. Sensitization of human colon cancer cells to trail-mediated apoptosis. J Gastrointest Surg 5:56-65.
252. Vignati, S., A. Codegoni, F. Polato and M. Broggini. 2002. Trail activity in human ovarian cancer cells. Potentiation of the action of cytotoxic drugs. Eur J Cancer 38:177-183.
253. Cuello, M., S. A. Ettenberg, M. M. Nau and S. Lipkowitz. 2001. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 81:380-390.
254. Mizutani, Y., M. Nakao, O. Ogawa, O. Yoshida, B. Bonavida and T. Miki. 2001. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J Urol 165:263-270.
255. von Haefen, C., B. Gillissen, P. G. Hemmati, J. Wendt, D. Guner, A. Mrozek, C. Belka, B. Dorken and P. T. Daniel. 2004. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 23:8320-8332.
256. Mizutani, Y., H. Nakanishi, O. Yoshida, M. Fukushima, B. Bonavida and T. Miki. 2002. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5 -fluorouracil. Eur J Cancer 38:167-176.
257. Singh, T. R., S. Shankar and R. K. Srivastava. 2005. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene.
258. Fandy, T. E., S. Shankar, D. D. Ross, E. Sausville and R. K. Srivastava. 2005. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7:646-657.
259. Sonnemann, J., J. Gange, K. S. Kumar, C. Muller, P. Bader and J. F. Beck. 2005. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest New Drugs 23:99-109.
260. Vanoosten, R. L., J. M. Moore, A. T. Ludwig and T. S. Griffith. 2005. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 11:542-552.
261. Inoue, S., M. MacFarlane, N. Harper, L. M. Wheat, M. J. Dyer and G. M. Cohen. 2004. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11 Suppl 2:S193-206.
262. Wendt, J., C. von Haefen, P. Hemmati, C. Belka, B. Dorken and P. T. Daniel. 2005. TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene in press.
263. 2-phase arrest in combined effect of TRAIL and ionizing radiation. Acta Biochim Pol in press.
264. Ciusani, E., D. Croci, M. Gelati, C. Calatozzolo, F. Sciacca, L. Fumagalli, M. Balzarotti, L. Fariselli, A. Boiardi and A. Salmaggi. 2005. in vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. J Neurooncol 71:19-25.
265. Shankar, S., T. R. Singh and R. K. Srivastava. 2004. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 61:35-49.
266. Kim, M. R., J. Y. Lee, M. T. Park, Y. J. Chun, Y. J. Jang, C. M. Kang, H. S. Kim, C. K. Cho, Y. S. Lee, H. Y. Jeong and S. J. Lee. 2001. Ionizing radiation can overcome resistance to TRAIL in TRAIL-resistant cancer cells. FEBS Lett 505:179-184.
267. Gong, B. and A. Almasan. 2000. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res 60:5754-5760.
268. Yamanaka, T., K. Shiraki, K. Sugimoto, T. Ito, K. Fujikawa, M. Ito, K. Takase, M. Moriyama, T. Nakano and A. Suzuki. 2000. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32:482-490.
269. Gliniak, B. and T. Le. 1999. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 59:6153-6158.
270. Shankar, S., X. Chen and R. K. Srivastava. 2005. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62:165-186.
271. Eggert, A., M. A. Grotzer, T. J. Zuzak, B. R. Wiewrodt, R. Ho, N. Ikegaki and G. M. Brodeur. 2001. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61:1314-1319.
272. Grotzer, M. A., A. Eggert, T. J. Zuzak, A. J. Janss, S. Marwaha, B. R. Wiewrodt, N. Ikegaki, G. M. Brodeur and P. C. Phillips. 2000. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 19:4604-4610.
273. Mori, T., R. Doi, E. Toyoda, M. Koizumi, D. Ito, K. Kami, A. Kida, T. Masui, Y. Kawaguchi and K. Fujimoto. 2005. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery 138:71-77.
274. Brooks, A. D. and T. J. Sayers. 2005. Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother 54:499-505.
275. Vigneswaran, N., J. Wu, N. Nagaraj, K. Adler-Storthz and W. Zacharias. 2005. Differential susceptibility of metastatic and primary oral cancer cells to TRAIL-induced apoptosis. Int J Oncol 26:103-112.
276. Park, J. W., M. G. Wong, M. Lobo, W. C. Hyun, Q. Y. Duh and O. H. Clark. 2003. Modulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by chemotherapy in thyroid cancer cell lines. Thyroid 13:1103-1110.
277. Kang, J., R. R. Kisenge, H. Toyoda, S. Tanaka, J. Bu, E. Azuma and Y. Komada. 2003. Chemical sensitization and regulation of TRAIL-induced apoptosis in a panel of B-lymphocytic leukaemia cell lines. Br J Haematol 123:921-932.
278. Sah, N. K., A. Munshi, J. F. Kurland, T. J. McDonnell, B. Su and R. E. Meyn. 2003. Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J Biol Chem 278:20593-20602.
279. Yoshida, T., T. Shiraishi, S. Nakata, M. Horinaka, M. Wakada, Y. Mizutani, T. Miki and T. Sakai. 2005. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res 65:5662-5667.
280. Van Valen, F., S. Fulda, B. Truckenbrod, V. Eckervogt, J. Sonnemann, A. Hillmann, R. Rodl, C. Hoffmann, W. Winkelmann, L. Schafer, B. Dockhorn-Dworniczak, T. Wessel, J. Boos, K. M. Debatin and H. Jurgens. 2000. Apoptotic responsiveness of the Ewing's sarcoma family of tumors to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Cancer 88:252-259.
281. Nikrad, M., T. Johnson, H. Puthalalath, L. Coultas, J. Adams and A. S. Kraft. 2005. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3 -only proteins Bik and Bim. Mol Cancer Ther 4:443-449.
282. Lashinger, L. M., K. Zhu, S. A. Williams, M. Shrader, C. P. Dinney and D. J. McConkey. 2005. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21 -dependent mechanism in human bladder and prostate cancer cells. Cancer Res 65:4902-4908.
283. Matta, H. and P. M. Chaudhary. 2005. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther 4:77-82.
284. Yin, D., H. Zhou, T. Kumagai, G. Liu, J. M. Ong, K. L. Black and H. P. Koeffler. 2005. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24:344-354.
285. Vasilevskaya, I. A. and J. O'Dwyer P. 2005. 17-Allylamino-17 -demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem Pharmacol 70:580-589.
286. Rokhlin, O. W., N. V. Guseva, A. F. Taghiyev, R. A. Glover and M. B. Cohen. 2004. Multiple effects of N-alpha-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines. Cancer Biol Ther 3:761-768.
287. Puduvalli, V. K., D. Sampath, J. M. Bruner, J. Nangia, R. Xu and A. P. Kyritsis. 2005. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10:233-243.
288. Rokhlin, O. W., A. F. Taghiyev, N. V Guseva, R. A. Glover, P. M. Chumakov, J. E. Kravchenko and M. B. Cohen. 2005. Androgen regulates apoptosis induced by TNF-R family ligands via multiple signaling pathways in LNCaP. Oncogene in press.
289. Martelli, A. M., P. L. Tazzari, G. Tabellini, R. Bortul, A. M. Billi, L. Manzoli, A. Ruggeri, R. Conte and L. Cocco. 2003. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid and ionizing radiation of human leukemia cells. Leukemia 17:1794-1805.
290. Cuello, M., S. A. Ettenberg, A. S. Clark, M. M. Keane, R. H. Posner, M. M. Nau, P. A. Dennis and S. Lipkowitz. 2001. Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61:4892-4900.
291. Teraishi F, K. S., Watanabe T, Tango Y, Kawashima T, Umeoka T, Nisizaki M, Tanaka N, Fujiwara T. 2005. ZD1839 (Gefitinib, "Iressa"), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett in press.
292. Park, S. Y. and D. W. Seol. 2002. Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 295:515-518.
293. Kim, K. M. and Y. J. Lee. 2005. Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway. Oncogene 24:355-366.
294. Kasuga, C., T. Ebata, N. Kayagaki, H. Yagita, M. Hishii, H. Arai, K. Sato and K. Okumura. 2004. Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NF-kappaB inhibitors. Cancer Sci 95:840-844.
295. Hyer, M. L., R. Croxton, M. Krajewska, S. Krajewski, C. L. Kress, M. Lu, N. Suh, M. B. Sporn, V. L. Cryns, J. M. Zapata and J. C. Reed. 2005. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 65:4799-4808.
296. Suh, W. S., Y. S. Kim, A. D. Schimmer, S. Kitada, M. Minden, M. Andreeff, N. Suh, M. Sporn and J. C. Reed. 2003. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving down-regulation of FLIP and sensitization to TRAIL. Leukemia 17:2122-2129.
297. Jung, E. M., J. H. Lim, T. J. Lee, J. W. Park, K. S. Choi and T. K. Kwon. 2005. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 (DR5). Carcinogenesis in press.
298. Deeb, D., H. Jiang, X. Gao, M. S. Hafner, H. Wong, G. Divine, R. A. Chapman, S. A. Dulchavsky and S. C. Gautam. 2004. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther 3:803-812.
299. Deeb, D., Y. X. Xu, H. Jiang, X. Gao, N. Janakiraman, R. A. Chapman and S. C. Gautam. 2003. Curcumin (diferuloylmethane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2:95-103.
300. Nozawa, F., A. Itami, M. Saruc, M. Kim, J. Standop, K. S. Picha, K. H. Cowan and P. M. Pour. 2004. The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and Genistein is effective in inhibiting pancreatic cancer growth. Pancreas 29:45-52.
301. Lacour, S., A. Hammann, A. Wotawa, L. Corcos, E. Solary and M. T. Dimanche-Boitrel. 2001. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 61:1645-1651.
302. Jazirehi, A. R., C. P. Ng, X. H. Gan, G. Schiller and B. Bonavida. 2001. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clin Cancer Res 7:3874-3883.
303. Olsson, A., T. Diaz, M. Aguilar-Santelises, A. Osterborg, F. Celsing, M. Jondal and L. M. Osorio. 2001. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 15:1868-1877.
304. Matsuzaki, H., B. M. Schmied, A. Ulrich, J. Standop, M. B. Schneider, S. K. Batra, K. S. Picha and P. M. Pour. 2001. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res 7:407-414.
305. Park, Y. W., J. D. Ji, J. S. Lee, D. W Ryang and D. H. Yoo. 2003. Actinomycin D renders cultured synovial fibroblasts susceptible to tumor necrosis factor related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Scand J Rheumatol 32:356-363.
306. Rohn, T. A., B. Wagenknecht, W. Roth, U. Naumann, E. Gulbins, P. H. Krammer, H. Walczak and M. Weller. 2001. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53 -independent but may involve enhanced cytochrome c release. Oncogene 20:4128-4137.
307. Nimmanapalli, R., C. L. Perkins, M. Orlando, E. O'Bryan, D. Nguyen and K. N. Bhalla. 2001. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 61:759-763.
308. Nimmanapalli, R., M. Porosnicu, D. Nguyen, E. Worthington, E. O'Bryan, C. Perkins and K. Bhalla. 2001. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 7:350-357.
309. Lu, M., T. Kwan, C. Yu, F. Chen, B. Freedman, J. M. Schafer, E. J. Lee, J. L. Jameson, V. C. Jordan and V. L. Cryns. 2005. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem 280:6742-6751.
310. Seki, N., Y. Hayakawa, A. D. Brooks, J. Wine, R. H. Wiltrout, H. Yagita, J. E. Tanner, M. J. Smyth and T. J. Sayers. 2003. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res 63:207-213.
311. Wang, S. and W. S. El-Deiry. 2004. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5 -fluorouracil. Cancer Res 64:6666-6672.
312. Finnberg, N., J. J. Gruber, P. Fei, D. Rudolph, A. Bric, S. H. Kim, T. F. Burns, H. Ajuha, R. Page, G. S. Wu, Y. Chen, W. G. McKenna, E. Bernhard, S. Lowe, T. Mak and W. S. El-Deiry. 2005. DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol 25:2000-2013.